An interventional study of Automatic follow-up recommendation and As-needed follow-up recommendation in Children With Medical Complexity, Respiratory Tract Infections (RTI) and Urinary Tract Infection (UTI), sponsored by Seattle Children's Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 1 Year to 16 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Seattle Children's Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 210 studies in Respiratory Tract Infections with a site in United States — 20 open to participants now, 28 under way, 5 of them phase 3. Respiratory Tract Infections · United States.
Among the 210 studies in Respiratory Tract Infections with a site in United States, this one is the 74th largest by planned enrollment of the 160 interventional ones that give a count, is one of 9 that started in 2026, is one of 66 with no phase, reaches primary completion later than 23 of the 26 other live ones, and was the 210th registered.
753 studies on the registry are indexed under Respiratory Tract Infections; 112 are open to participants now.
Browse Respiratory Tract Infections studies →20 of the 210 studies in Respiratory Tract Infections with a site in United States are open now. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 7–17 · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
University Hospital, Grenoble · Sites in United States, France, Germany and 2 more countries
Ages 60+
Timothy Shope · Sites in United States
Ages 6 mo–24 mo
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 73 Respiratory Tract Infections studies recruiting now, 33 (45%) set no upper age limit and 32 (44%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 1 Year to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
210 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 42 · Phase 3 22 · Phase 4 14
First in 1997; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is below the median of 200 across 542 interventional studies indexed under Respiratory Tract Infections.
Median enrollment 137 across the 160 interventional studies, 558 across the 48 observational. Of the 172 that completed or were terminated, 67 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
85 of 210 have an industry lead sponsor. The 10 most frequent:
Seattle Children's Hospital is the lead sponsor of 217 studies on the registry; 46 are open to participants now.
Seattle Children's Hospital has 2 studies filed under Respiratory Tract Infections — fewer than ten, so there is no comparison to draw.
14 of the studies in Respiratory Tract Infections with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-12 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05474430Philip PolgreenEstimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity | 2026-12 |
Add all 14 to your calendar (.ics) → With an account.
Among the 210 studies in Respiratory Tract Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Children with medical complexity often receive a recommendation to see an outpatient clinician soon after leaving the hospital. It is uncertain whether every child needs this routine visit or whether follow-up can be guided by the family's concerns and the child's recovery. AFTERCARE is a multicenter pilot randomized trial comparing these two follow-up recommendations for children hospitalized with an acute infection.
Families will be assigned by chance to receive either a recommendation to arrange follow-up with their usual outpatient clinician within seven days or a recommendation to seek follow-up if the child is not improving as expected or new concerns arise. Families in both groups may seek medical care whenever needed. The study will assess recruitment, follow-up data collection, delivery of the recommendations and acceptability. Caregiver surveys and medical record review will also describe outpatient visits and hospital returns. This pilot will inform the design of a larger trial, and is not designed to establish that the strategies are equally safe or effective.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Families are instructed to arrange follow-up with their usual outpatient clinician within seven days after hospital discharge.
Behavioral: Automatic follow-up recommendation
Families are instructed that follow-up is recommended if the child is not improving as expected or new concerns arise.
Behavioral: As-needed follow-up recommendation
Families are instructed to arrange follow-up with their usual outpatient clinician within seven days after hospital discharge. This is the clinician or team the family usually contacts first for health concerns and may be a generalist, complex-care clinician or specialist. Other specialist care continues as usual.
Families are instructed that follow-up is recommended if the child is not improving as expected or new concerns arise. This recommendation concerns follow-up with the clinician or team the family usually contacts first for health concerns, which may be a generalist, complex-care clinician or specialist. Other specialist care continues as usual.
Eligible hospitalizations per site per month
Number of hospitalizations confirmed as initially eligible through study screening per month that a study site is open to recruitment.
Time frame: During recruitment, anticipated to last approximately 2 years.
Clinician acceptance rate
Percentage of consented patients with known objection status for whom no clinician objected to randomization, including no reply after clinician notification and the response period.
Time frame: During the initial hospitalization, before randomization or the end of recruitment for that patient (up to hospital day 30).
Family consent rate
Percentage of initially eligible families offered study participation who provide consent.
Time frame: During recruitment in the initial hospitalization (up to hospital day 30).
Difference in seven-day primary care follow-up between study arms
Automatic minus as-needed difference in the percentage of patients with known follow-up status who have a clinical visit or call with their regular doctor or usual care team within seven days after discharge.
Time frame: Within 7 days after hospital discharge.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Sep 2028, 23 months later.
Of 119 non-industry interventional studies with no phase under Respiratory Tract Infections, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's planned 23 months is above that.
Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Tract Infections →